New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More

Where is Immunovant (IMVT) Heading According to Analysts?

By Noor Ul Ain Rehman | September 30, 2025, 4:00 AM

Immunovant, Inc. (NASDAQ:IMVT) is one of the best strong buy stocks to invest in according to Wall Street. On September 3, LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant, Inc. (NASDAQ:IMVT), keeping the price target at $50.00.

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings?

Similarly, BofA analyst Jason Gerberry maintained a buy rating on the stock but lowered the firm’s price target on Immunovant, Inc. (NASDAQ:IMVT) to $30 from $33.

Leerink Partners analyst Thomas Smith also expressed bullish sentiments for Immunovant, Inc. (NASDAQ:IMVT), reiterating a Buy rating with a $52.00 price target.

The analyst consensus rating for Immunovant, Inc. (NASDAQ:IMVT) is a Strong Buy, and the stock’s median price target of $16.23 implies an upside of 174.18% from current levels.

Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn).

While we acknowledge the potential of IMVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

Mentioned In This Article

Latest News

Sep-30
Sep-10
Sep-04
Sep-03
Sep-03
Aug-12
Aug-11
Jul-16
Jul-16
Jul-16
Jul-06
Jun-02
May-30
May-29
May-09